Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10)
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/43
A61P-035/00
C12Q-001/68
A61K-031/00
A61K-031/122
G01N-033/574
출원번호
US-0171419
(2014-02-03)
등록번호
US-9896731
(2018-02-20)
발명자
/ 주소
Narain, Niven Rajin
McCook, John Patrick
출원인 / 주소
Berg LLC
대리인 / 주소
McCarter & English, LLP
인용정보
피인용 횟수 :
0인용 특허 :
112
초록
Methods and formulations for treating onocological disorders in humans using Coenzyme Q10 are described.
대표청구항▼
1. A method for treating or preventing a skin oncological disorder in a human, wherein the skin oncological disorder is basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), the method comprising: topically administering a pharmaceutical composition comprising about 3% Coenzyme Q10 (CoQ10) to
1. A method for treating or preventing a skin oncological disorder in a human, wherein the skin oncological disorder is basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), the method comprising: topically administering a pharmaceutical composition comprising about 3% Coenzyme Q10 (CoQ10) to a target tissue of the human at a dose in the range of 0.1 to 0.5 milligrams of CoQ10 per square centimeter of skin such that treatment or prevention occurs, wherein the CoQ10 is in its oxidized form and has a purity between 95% and 100%, and wherein administration of the composition to the subject results in an increase of CoQ10 in the oxidized form in the subject. 2. The method of claim 1, wherein CoQ10 induces apoptosis or cell death mechanism in a cancerous cell of the oncological disorder. 3. The method of claim 1, wherein CoQ10 inhibits angiogenesis in a tumor of the oncological disorder. 4. The method of claim 1, wherein CoQ10 induces a modulation of immune-related elements within the microenvironment of a cancerous cell of the oncological disorder. 5. The method of claim 1, wherein CoQ10 induces a change in cell cycle control in a cancerous cell of the oncological disorder. 6. The method of claim 1, wherein a population of humans are treated and at least 25% of the population experiences a diminishment of symptoms as measured by art-recognized endpoints including tissue pathology, clinical observations, photographic analyses, CT-scan, MRI imaging, blood, serum, or plasma markers of cancer. 7. The method of claim 1, wherein a population of humans are treated and at least 25% of the population had a systemic Coenzyme Q10 level that was therapeutic for the disorder being treated. 8. The method of claim 1, wherein the concentration of Coenzyme Q10 in the tissues of the humans being treated is different than that of a control standard of human tissue representative of a healthy or normal state. 9. The method of claim 1, wherein the treatment occurs via an interaction of Coenzyme Q10 with a protein selected from the group consisting of HNF4-alpha, Bcl-xl, Bcl-xS, BNIP-2, Bcl-2, Birch, Bcl-2-L11 (Bim), XIAP, BRAF, Bax, c-Jun, Bmf, PUMA, cMyc, transaldolase 1, COQ1, COQ3, COQ6, prenyltransferase, 4-hydrobenzoate, neutrophil cytosolic factor 2, nitric oxide synthase 2A, superoxide dismutase 2, VDAC, Bax channel, ANT, Cytochrome c, complex 1, complex II, complex III, complex IV, Foxo 3a, DJ-1, IDH-1, Cpt1C, and Cam Kinase II and any one or more of genes listed in Tables 2-4 & 6-28. 10. The method of claim 1, wherein Coenzyme Q10 is applied in a topical vehicle to a target tissue at a dose of about 0.12 milligrams of coenzyme Q10 per square centimeter of skin. 11. The method of claim 1, wherein the oncological disorder is Squamous cell Carcinoma. 12. The method of claim 1, wherein the oncological disorder is Basal Cell Carcinoma. 13. The method of claim 1, wherein the oncological disorder is SCC, and wherein the method prevents the pre-cancerous lesion actinic keratosis from progressing into SCC. 14. The method of claim 1, wherein the composition comprising Coenzyme Q10 is topically applied one or more times per 24 hours for six weeks or more. 15. The method of claim 1, wherein the composition comprising Coenzyme Q10 is administered in the form of a CoQ10 cream. 16. The method of claim 1, further comprising an additional treatment regimen selected from the group consisting of surgery, radiation, hormone therapy, antibody therapy, therapy with growth factors, therapy with cytokines, and chemotherapy. 17. The method of claim 1, wherein the pharmaceutical composition comprises a CoQ10 cream comprising: (1) a phase A having Capric/Caprylictriglyceride at 4.00% w/w of the composition, cetyl alcohol at 2.00% w/w of the composition, stearyl alcohol at 1.5% w/w, glyceryl stearate and PEG-100 at 4.5% w/w;(2) a phase B having glycerin at 2.00% w/w, propylene glycol at 1.5% w/w, ethoxydiglycol at 5.0% w/w, phenoxyethanol at 0.475% w/w, a carbomer dispersion at 40.00% w/w, purified water at 16.725% w/w;(3) a phase C having triethanolamine at 1.300% w/w, lactic acid at 0.500% w/w, sodium lactate solution at 2.000% w/w, water at 2.5% w/w;(4) a phase D having titanium dioxide at 1.000% w/w; and(5) a phase E having CoQ10 21% concentrate at 15.000% w/w. 18. The method of claim 17, wherein the carbomer dispersion comprises water, phenoxyethanol and propylene glycol.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (112)
Hoppe Udo,DEX ; Sauermann Gerhard,DEX ; Schreiner Volker,DEX ; Steiger Klaus-Michael,DEX, Active substances and compositions for the therapy of senile xerosis.
Zysman Alexandre (Paris FRX) Sebag Henri (Paris FRX) Ribier Alain (Paris FRX) Vanlerberghe Guy (Villevaude FRX) Mahieu Claude (Paris FRX) Berthelot Claude (Les Pavillons Sous Bois FRX), Cosmetic, dermo-pharmaceutical or vesicle-containing composition including clycerol-derived compounds.
Lee,Sean; Kessler,Susanna; Forberich,Oliver; Buchwar,Claire; Greenspan,David C., Cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same.
Keller Brian C. ; Fisher Daniel L. ; Kiss Steven, Delivery of biologically active material in a liposomal formulation for administration into the mouth.
Haynes Lynn C. (Morris Plaines NJ) Levine Harry (Morris Plaines NJ) Finley John W. (Whippany NJ), Liposome composition for the stabilization of oxidizable substances.
Terkeltaub,Robert; Murphy,Anne N.; Dykens,James A.; Ghosh,Soumitra S.; Davis,Robert E.; Granston, Jr.,Andrew E., Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass.
Casey Adria C. (Ridgefield CT) Adler Alan D. (West Redding CT) Premuzic Eugene T. (Montauk NY), Methods of stimulating host defense system with coenzymes Q4to Q13.
Myers Charles E. (Rockville MD) Trepel Jane (Bethesda MD) Sausville Edward (Silver Spring MD) Samid Dvorit (Rockville MD) Miller Alexandra (Hyattsville MD) Curt Gregory (Rockville MD), Monoterpenes, sesquiterpenes and diterpenes as cancer therapy.
Gilloteaux,Jacques; Taper,Henryk S.; Jamison,James M; Summers,Jack L., Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K.
Miyake,Koichiro; Hashimoto,Shinichi; Motoyama,Hiroaki; Ozaki,Akio; Seto,Haruo; Kuzuyama,Tomohisa; Takahashi,Shunji, Process for producing isoprenoid compounds by microorganisms and a method for screening compounds with antibiotic or weeding activity.
Miyake,Koichiro; Hashimoto,Shinichi; Motoyama,Hiroaki; Ozaki,Akio; Seto,Haruo; Kuzuyama,Tomohisa; Takahashi,Shunji, Process for producing isoprenoid compounds by microorganisms and a method for screening compounds with antibiotic or weeding activity.
Frederiksen Lene (Basel CHX) Anton Klaus (Basel CHX) van Hoogevest Peter (Riehen CHX), Process for the preparation of a liposome dispersion under elevated pressure contents.
Harm M. Deckers CA; Gijs van Rooijen CA; Joseph Boothe CA; Janis Goll CA; Maurice M. Moloney CA, Products for topical applications comprising oil bodies.
Kunsch,Charles; Varner,Signe E.; Chen,Xilin; Luchoomun,Jayraz, Protection against oxidative stress and inflammation by a cytoprotective response element.
Hoppe, Udo; Schreiner, Volker; Stab, Franz, Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones.
Unger Evan C. ; Fritz Thomas A. ; Matsunaga Terry ; Ramaswami VaradaRajan ; Yellowhair David ; Wu Guanli, Targeted gas and gaseous precursor-filled liposomes.
Takashi Hanioka JP; Judson T. McRee ; Karl Folkers, Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease.
Grazia Sears IT; Janos Feher IT, Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiguinones and methods of using same.
Schonrock Uwe,DEX ; Steckel Friedhelm,DEX ; Kux Ulrich,JPX ; Inoue Kazuo,JPX, Use of salicin as an anti-irritative active compound in cosmetic and topical dermatological preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.